Biotech · Private company
Innovent Biologics (Suzhou) Co. Ltd.
Track this companyFree. Adds Innovent Biologics (Suzhou) Co. Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials124 recruiting or active
Pipeline programs15From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline15
- CisplatinPhase 3 · Esophageal Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- FluorouracilPhase 3 · Esophageal Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 3 · Esophageal Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- SintilimabPhase 3 · Esophageal Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- IBI314Phase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- IBI363Phase 2 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Sintilimab + IBI110Phase 2 · Unresectable Cutaneous MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- AzacitidinePhase 1 · MDSClinicalTrials.gov · fetched Nov 12, 2026
- FOLFIRINOX/mFOLFIRINOXPhase 1 · Locally Advanced Unresectable or Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- IBI188Phase 1 · Advanced MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- IBI188Phase 1 · MDSClinicalTrials.gov · fetched Nov 12, 2026
- IBI308Phase 1 · Advanced/Metastatic Solid MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injectionPhase 1 · Advanced Malignant Tumors LymphomasClinicalTrials.gov · fetched Nov 12, 2026
- IBI343Phase 1 · Locally Advanced Unresectable or Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- mFOLFOXPhase 1 · Locally Advanced Unresectable or Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials12
- A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung CancerPHASE3 · RECRUITING · started Nov 26, 2025ClinicalTrials.gov NCT07217301 · fetched Nov 12, 2026
- IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid TumorsPHASE1 · RECRUITING · started Jan 10, 2025ClinicalTrials.gov NCT06349408 · fetched Nov 12, 2026
- A Study of IBI363 in Subjects with Advanced Solid MalignanciesPHASE2 · RECRUITING · started Apr 8, 2024ClinicalTrials.gov NCT06281678 · fetched Nov 12, 2026
- A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous MelanomaPHASE1_PHASE2 · WITHDRAWN · started Nov 1, 2022ClinicalTrials.gov NCT05572463 · fetched Nov 12, 2026
- A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid TumorsPHASE1 · RECRUITING · started Oct 26, 2022ClinicalTrials.gov NCT05458219 · fetched Nov 12, 2026
- A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19PHASE1_PHASE2 · TERMINATED · started Jan 6, 2022ClinicalTrials.gov NCT05162365 · fetched Nov 12, 2026
- Sintilimab in Cancer of Unknown PrimaryPHASE2 · COMPLETED · started Aug 26, 2021ClinicalTrials.gov NCT05024968 · fetched Nov 12, 2026
- A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced CancersPHASE1 · COMPLETED · started Jan 14, 2021ClinicalTrials.gov NCT04338659 · fetched Nov 12, 2026
- A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDSPHASE1 · SUSPENDED · started Aug 24, 2020ClinicalTrials.gov NCT04511975 · fetched Nov 12, 2026
- A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and LymphomasPHASE1 · COMPLETED · started Feb 19, 2019ClinicalTrials.gov NCT03763149 · fetched Nov 12, 2026
- Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )PHASE3 · COMPLETED · started Dec 24, 2018ClinicalTrials.gov NCT03748134 · fetched Nov 12, 2026
- IBI308 in Subjects With Advanced/Metastatic Solid MalignanciesPHASE1 · COMPLETED · started Jun 27, 2018ClinicalTrials.gov NCT03568539 · fetched Nov 12, 2026